Therefore, validating BRCA1 promoter methylation detection using this technique as a diagnostic and prognostic biomarker has the potential to improve early detection and treatment options, ultimately reducing the morbidity and mortality associated with breast cancer in LMICs. The gene discussed is BRCA1; the disease is breast cancer.